In addition to classical chemotherapeutic agents, third-generation ABC transporter inhibitors have also been demonstrated to be potent inhibitors that retain targeted drugs, including small-molecule tyrosine kinase inhibitors, within cancer cells. Here, ABCG2 is linked to cancer.